Caltagirone Editore SpA (BIT:CED)

Verve Therapeutics Balance Sheet

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	3.32	3.97	16.04	23.99	66.61	100.5
Short-Term Investments	9.74	19.83	18.16	-	-	-
Cash & Short-Term Investments	13.06	23.8	34.2	23.99	66.61	100.5
Cash Growth	-75.89%	-30.42%	42.55%	-63.98%	-33.72%	-10.56%
Accounts Receivable	34.95	39.28	35.93	34.25	37.07	41.03
Other Receivables	7.63	11.65	3.95	2.41	3.22	0.69
Receivables	42.58	50.93	39.88	36.66	40.28	41.72
Inventory	1.99	2.05	2.18	2.53	1.7	1.59
Prepaid Expenses	1.07	0.59	0.43	0.6	0.41	0.38
Other Current Assets	0	-	-	-0	-	-
Total Current Assets	58.71	77.37	76.69	63.78	109	144.18
Property, Plant & Equipment	34.45	37.67	40.32	44.73	46.71	40.42
Long-Term Investments	491.34	386.88	270.45	231.88	196.65	108.16
Other Intangible Assets	77.35	77.34	92.23	92.04	103.49	103.87
Long-Term Deferred Tax Assets	57.39	57.03	55.56	53.22	52.84	53.39
Other Long-Term Assets	0.16	0.14	0.14	0.15	0.14	0.14
Total Assets	719.4	636.44	535.38	485.8	508.82	450.16
Accounts Payable	26.41	27.03	21.14	19.91	19.84	19.65
Accrued Expenses	8.66	8.66	8.55	8.03	8.32	9.05
Short-Term Debt	13.42	13.94	7.61	7.52	5.77	7.41
Current Portion of Long-Term Debt	-	-	0.54	0.67	-	-
Current Portion of Leases	3.73	3.96	3.75	3.62	3.45	3.5
Current Income Taxes Payable	-	-	0.01	-	1.06	-
Current Unearned Revenue	1.65	1.88	1.54	1.32	1.19	1.47
Other Current Liabilities	17.59	17.36	17.33	17.41	18.6	21.88
Total Current Liabilities	71.46	72.82	60.47	58.47	58.23	62.96
Long-Term Leases	6.63	8.62	9.61	12.13	12.15	3.56
Long-Term Unearned Revenue	0.96	1.2	0.98	1.15	1.27	1.25
Long-Term Deferred Tax Liabilities	21.85	17.85	18.69	17.12	20.09	27.55
Other Long-Term Liabilities	0.22	0.22	0.23	0.36	0.21	0.76
Total Liabilities	109.51	109.67	100.01	100.54	105.82	110.89
Common Stock	125	125	125	125	125	125
Additional Paid-In Capital	459.13	459.13	459.13	459.13	459.13	459.13
Retained Earnings	-170.79	-180.64	-187.85	-201.62	-209.75	-238.48
Treasury Stock	-23.64	-23.64	-23.64	-23.64	-23.64	-23.64
Comprehensive Income & Other	220.19	146.93	62.74	26.4	52.26	17.27
Shareholders' Equity	609.89	526.77	435.37	385.26	403	339.27
Total Liabilities & Equity	719.4	636.44	535.38	485.8	508.82	450.16
Total Debt	23.78	26.52	21.51	23.94	21.36	14.48
Net Cash (Debt)	-10.72	-2.72	12.7	0.06	45.25	86.02
Net Cash Growth	-	-	21793.10%	-99.87%	-47.40%	-8.27%
Net Cash Per Share	-0.10	-0.03	0.12	0.00	0.42	0.81
Filing Date Shares Outstanding	106.79	106.79	106.79	106.79	106.79	106.79
Total Common Shares Outstanding	106.79	106.79	106.79	106.79	106.79	106.79
Working Capital	-12.75	4.55	16.22	5.31	50.77	81.22
Book Value Per Share	5.71	4.93	4.08	3.61	3.77	3.18
Tangible Book Value	532.54	449.43	343.14	293.22	299.51	235.4
Tangible Book Value Per Share	4.99	4.21	3.21	2.75	2.80	2.20
Land	61.45	61.45	60.29	60.29	60.29	60.29
Machinery	98.58	98.57	99.61	99.39	99.28	99.14
Construction In Progress	0.05	0.05	0.04	-	-	-

Updated Jul 30, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.